Two new vaccines on the way – with more to follow this year

Half of UK adults have had a first jab, and future supplies of millions of doses look assured

The workhorses

Two very different jabs have been responsible for inoculating Britain’s strikingly high number of vaccine recipients – with more than half of the country’s adult population having now received a first dose and several million people having received second doses. The Pfizer/BioNTech vaccine uses pieces of the Covid virus’s genetic code which, after injection, enter cells and instructs them to start making pieces of virus protein, which stimulate a person’s immune system. The Oxford/AstraZeneca vaccine uses a chimp cold virus (genetically engineered so it cannot trigger infection in people) which has been re-modified to carry viral genes into cells so they make pieces of Covid-19 viruses – and stimulate immune systems.

A type of rare blood clot has been reported in some recipients, with the UK Medicines and Healthcare products Regulatory Agency (MHRA) announcing last week it had received 30 such reports out of the 18.1m recipients of the vaccine: roughly one case for every 600,000 recipients. “The extreme rarity of these events … means the risk-benefit decision facing people invited to receive vaccines is very straightforward: the vaccine is by far the safest choice in terms of minimising individual risk of serious illness or death,” said Professor Adam Finn of Bristol University.

The cavalry is coming…

As existing supplies are used to provide those having had their first jabs with their secondary boosters, two further vaccines are expected to be rolled out to help the British government meet its goal of having every adult in the country vaccinated by summer. The first of these is the Moderna vaccine, which has already been used widely in the US and which is based on a technology that is very similar to the one behind the Pfizer/BioNTech vaccine. Britain has agreed to buy 17m doses of the Moderna vaccine, and the first doses – about 500,000 – are expected to arrive in the next few weeks.

The other jab due to arrive in the UK in the near future is being made by the US firm Novavax and uses genetically engineered cells, extracted from moths, to make pieces of coronavirus protein that will stimulate anti-Covid responses when injected into people. The company says it expects to be given approval in the US and UK next month and will manufacture its vaccines in 20 locations on four continents, which should help avoid cross-border supply issues. Novavax expects to be able to make 2bn doses of its vaccine this year.

On the horizon

Two further vaccines are likely to appear in the UK later this year. The first is the Janssen/Johnson & Johnson vaccine, which, like the Oxford/AstraZeneca version, uses a weakened common cold virus to deliver instructions for making the Covid-19 surface spike protein to our cells. Expressed on their surfaces, the protein triggers an immune response. Importantly, it is hoped that only a single jab of the Janssen vaccine will be needed to provide protection against Covid-19. The UK has ordered 30m doses, though it has yet to be approved by the MRA.

Covid data

The second vaccine likely to be ready for use in the UK by the end of the year is expected to be manufactured by France-based Valneva at its new manufacturing facility in West Lothian, Scotland. The vaccine contains inactivated Covid-19 particles that stimulate the body’s immune system into manufacturing antibodies that swarm round invading viruses and block their actions. The vaccine is still undergoing clinical trials. However, if approved, it is likely be rolled out around the country by the end of the year. The UK has ordered 100m doses.


Robin McKie

The GuardianTramp

Related Content

Article image
I’ve had my first vaccine jab. It gives me hope of liberation... but not yet
Exactly a year after his first story about coronavirus, our science editor received the Pfizer injection last week. Here he reflects on a remarkable scientific achievement

Robin McKie Science Editor

24, Jan, 2021 @7:00 AM

Article image
Vaccine experts defend UK decision to delay second Pfizer Covid jab
Medics told they risk undermining public confidence by querying policy of three-month gap between doses

Michael Savage, Robin McKie and James Tapper

23, Jan, 2021 @10:30 PM

Article image
From Pfizer to Moderna: who's making billions from Covid-19 vaccines?
The companies in line for the biggest windfalls – and the shareholders who have already made fortunes

Julia Kollewe

06, Mar, 2021 @11:55 AM

Article image
The Oxford Covid jab is delivered this week. But when will vaccines bring results?
Fall or rise in coronavirus cases will not initially be a good measure of efficacy, say scientists devising ways to audit progress

Robin McKie Science editor

03, Jan, 2021 @7:15 AM

Article image
The Guardian view on coronavirus and vaccine scepticism: time to act | Editorial
Editorial: Plans for mass immunisation against Covid-19 are developing fast, but concerns must be addressed


22, Nov, 2020 @6:30 PM

Article image
Global Covid vaccine rollout threatened by shortage of vital components
Pharmaceutical firms warn of delays to items such as the large bags in which vaccine cells are grown

James Tapper

10, Apr, 2021 @2:44 PM

Article image
Will Covid vaccines protect us against new variants? | Julian Tang
Outbreaks such as the South African variant that’s emerged in south London will require constant vigilance as lockdown eases, says clinical virologist Julian Tang

Julian Tang

14, Apr, 2021 @12:52 PM

Article image
Moderna, Pfizer or AstraZeneca? The ridiculous, diverting rise of vaccine envy
Casual vaccine chat is today’s only form of small talk, so it’s not surprising it would take a lightheartedly tribal turn. Ultimately, of course, gratitude is at the heart of the conversation

Zoe Williams

21, Jun, 2021 @6:00 AM

Article image
‘Wall of secrecy’ in Pfizer contracts as company accused of profiteering
US company faces scrutiny over Covid profits after UK agrees to secrecy clause

Jon Ungoed-Thomas

05, Dec, 2021 @6:30 AM

Article image
UK orders extra Covid vaccines for autumn 2022 booster campaign
Pfizer reportedly asked to supply 35m more doses, with final go-ahead for this year’s programme still awaited

Andrew Sparrow Political correspondent

11, Aug, 2021 @9:51 AM